NAD+ vs Comparable Research Peptides: Side-by-Side Data

How to use this checklist

This is a comparison checklist for evaluating research-grade NAD+ against other commonly catalogued research compounds on the dimensions a sourcing decision actually turns on. NAD+ is supplied by Proxiva Peptides as a lyophilized powder for in-vitro research use only. There is no comparison of biological effect or potency anywhere here — that would be non-compliant and beside the point. Work the checklist top to bottom; each item is a pass/fail a buyer can apply before purchase, not a judgment that needs the material in hand.

Check 1: is it lyophilized and handled as a resting dry state

The first comparison item is form. NAD+ should be supplied lyophilized and handled as a dry, sealed resting state, the same discipline that applies to other stability-sensitive catalogue compounds. The fail condition is a pre-dissolved offering with unspecified handling history or a powder with no stated format reasoning. On this item, NAD+ from a verified supplier sits with the documented dry-state compounds, not with anything sold on price alone.

Check 2: does every lot carry its own Certificate of Analysis

The second item is the one that genuinely separates catalogue compounds, and it separates by supplier far more than by molecule. Pass requires a per-lot Certificate of Analysis with HPLC quantification and mass-spec identity confirmation. A generic certificate, or one for a different batch, is a fail. The honest comparison is not NAD+ against compound X; it is NAD+ with a per-lot COA against anything, including NAD+, without one.

Check 3: is the storage discipline the one the lab already runs

The third item asks whether NAD+ slots into the lab’s existing handling regime or demands a separate one. Across stability-sensitive catalogue compounds the storage story rhymes: keep the dry state dry and sealed, minimize time in solution, aliquot against freeze-thaw, protect the cold chain. NAD+ passes this item by being unremarkable in the best sense — same discipline, no special regime — which is an operational advantage, not a deficiency.

Check 4: can the supplier’s provenance be reconstructed later

The fourth item is the one every experienced buyer’s comparison eventually collapses onto: can the supplier’s provenance be defended in a record months after purchase. Form and storage are mostly solved problems with known answers. Documentation is binary. What still varies widely is whether the entity behind the listing can show where material came from and stand behind its analysis. NAD+ from Proxiva Peptides is positioned on the reconstructable side of this item.

Check 5: is the fulfillment path short and transparent

The fifth item scores the route. Transit and cold-chain exposure are real, mostly invisible inputs to arrival condition, and a shorter, transparent, domestically fulfilled path reduces unmanaged hours and unknowns. US fulfillment is a risk-reduction property that belongs on the comparison checklist next to documentation, not in a footnote. A long, opaque route is a fail even when every other item passes.

Check 6: are the units normalized before price is compared

The sixth item is a discipline, not a property: do not compare price until items 1–5 are held constant. The classic error is comparing two NAD+ listings, or NAD+ against another compound, on price while documentation and provenance silently vary. That is not a comparison; it is two different things sharing a name. Price enters the checklist last, and only among listings that already passed everything above.

What the checklist removes from contention

Run items 1–5 across a field of NAD+ listings and most are eliminated before price is reached. That is the checklist working as intended: it converts an overwhelming set of options into the small set that are genuinely comparable, so the price comparison that remains is between equivalent, documented units rather than between a verified compound and an undocumented one wearing the same label.

Why the comparison rarely comes down to the molecule

Apply the checklist repeatedly and the same result appears: the decisive differences are almost never intrinsic to NAD+ against another catalogue compound. Form converges. Storage converges. What stays variable is documentation completeness and supplier verifiability — properties of the seller, not the molecule. The comparison that began as “which compound” resolves, nearly every time, into “which source can be defended later.”

The checklist as a receiving step too

Items 2 and 4 are not only pre-purchase filters; they are receiving checks. On arrival, the NAD+ lot number must reconcile to its Certificate of Analysis, and the provenance trail must be intact enough to reconstruct. A listing that passed the checklist at purchase but fails reconciliation at receipt has failed; the checklist is run twice, once to buy and once to accept.

Scoring the decision

A NAD+ source that clears all six items is comparable, on the axes that matter, to the best alternatives in the catalogue and is a defensible purchase almost regardless of headline price. One that fails any item is not cheaper; it is less documented or less traceable, with the gap priced to look like a saving. The checklist’s value is that it makes that distinction explicit before money moves.

A worked pass/fail example

Take two NAD+ listings, one cheaper. The cheaper one states “high purity” with no method, ships a generic certificate not tied to a lot, and routes through an opaque multi-leg path. The other states HPLC with mass-spec confirmation, ships a lot-specific Certificate of Analysis that reconciles to the vial, and fulfils domestically. On the checklist the first fails items 1 through 5 and never reaches the price comparison; the second passes and enters it. The headline price gap that looked like a saving was a documentation gap the price was hiding. Run honestly, the checklist usually ends here — most apparent NAD+ bargains do not survive item 2, and the ones that do are the only comparison worth finishing.

The comparison in one line

On the axes a buyer can actually evaluate — form, per-lot documentation, storage discipline, provenance, fulfillment, normalized price — NAD+ compares not against this or that other compound but against the difference between verified and unverified sourcing, and it is worth comparing only on the verified side of that line.

Frequently Asked Questions

RESEARCH USE ONLY. All products are intended strictly for in-vitro laboratory and research use only. Not for human or animal consumption; not a drug, food, or cosmetic; not intended to diagnose, treat, cure, or prevent any condition. Statements not evaluated by the FDA. Researchers are responsible for applicable-regulation compliance.